Johns Hopkins

The evolution of mobile technology use in clinical trials

Wednesday, October 18, 2017

William Osler, a founder of Johns Hopkins University, was a clinician ahead of his time. He was one of the first doctors to bring medical students out of the lecture hall and to the patient’s bedside — a revolutionary format change in its day. His 1892 book, The Principles and Practice of Medicine, was labeled as an “imaginative new curriculum” that prevailed for 50 years.1 Osler once said, “The good physician treats the disease; the great physician treats the patient who has the disease.”

[Read More]

Eisai, Johns Hopkins extend drug discovery collaboration

Wednesday, May 31, 2017

Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., and  Johns Hopkins University have extended their drug discovery collaboration through an exclusive licensing agreement. The agreement is for a license of compounds identified from collaborative research between Eisai’s Andover Innovative Medicines (AiM) Institute in Andover, Mass., and Johns Hopkins Drug Discovery (JHDD). The compounds were the outcome of research carried out in the laboratory of Professor Barbara Slusher Ph.D., MAS, Professor of Neurology, Neuroscience, Psychiatry, Medicine and Oncology at Johns Hopkins and the Director of JHDD, and is part of a broader ongoing collaborative research arrangement between Eisai and Johns Hopkins that is designed to translate new target discoveries into novel small molecule therapeutics for the development of medicines for neurology and oncology.

[Read More]

NIH funds seven international centers of excellence for Malaria research

Monday, April 24, 2017

The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, announced approximately $9 million in first-year funding, subject to availability, for seven malaria research centers around the world. The seven-year awards continue NIAID’s 2010 program that created the International Centers of Excellence for Malaria Research (ICEMRs) in regions where malaria is endemic. The awards fund three new and four existing centers that work in 14 countries in Africa, Asia and Latin America.

[Read More]

Industry reacts to proposed regulatory fee increase

Monday, March 27, 2017

President Trump’s proposed budget would require drug and device makers to pay more than double the current fees for regulatory approval, a concern that has many in the industry asking for more detail. The proposed budget posits the fee increases would improve the speed of regulatory approval, but specifics for how that outcome would be achieved have yet to be provided. The suggested budget also cuts nearly $6 billion from the NIH, which would greatly impact medical research funding.

[Read More]

Biogen appoints Anirvan Ghosh SVP, Research and Early Development

Friday, March 17, 2017

Biogen appointed Anirvan Ghosh, Ph.D., as senior vice president, Research and Early Development (RED). Dr. Ghosh will lead Biogen’s RED organization in the discovery and development of drug candidates from idea through proof of concept. He will report to Michael Ehlers, M.D., Ph.D., executive vice president, Head of Research and Development. Dr. Ghosh will begin his service at Biogen in April.

[Read More]

Johns Hopkins, MSCRF, BioCardia treat first patient with CardiAMP in ischemic heart failure trial

Wednesday, March 1, 2017

Johns Hopkins Medicine, the Maryland Stem Cell Research Fund (MSCRF) and BioCardia announced that the first patient has been treated in the pivotal phase III CardiAMP clinical trial of a cell-based therapy for the treatment of ischemic heart failure that develops after a heart attack. The first patient was treated at Johns Hopkins Hospital by a team led by Peter Johnston, M.D., a faculty member in the Department of Medicine and Division of Cardiology, and principal investigator of the trial at Johns Hopkins.

[Read More]

GeoVax forms scientific advisory board

Tuesday, January 3, 2017

GeoVax Labs, a biotechnology company specializing in developing human vaccines, has announced the formation of its inaugural Scientific Advisory Board (SAB) to provide expert guidance as the company advances its vaccine development for multiple targets including HIV, hemorrhagic fever (Ebola, Sudan, Marburg, Lassa), Zika virus, chronic Hepatitis B and immuno-oncology.

[Read More]

Bristol-Myers Squibb, Johns Hopkins collaborate on immuno-oncology research

Friday, November 11, 2016

Bristol-Myers Squibb has entered into a five-year research collaboration with the Johns Hopkins University. The collaboration is designed to identify mechanisms of response and resistance in patients whose cancer is being treated with checkpoint inhibitor-based immunotherapies, including Opdivo (nivolumab) monotherapy, or Opdivo in combination with Yervoy (ipilimumab) or other investigational immunotherapies.

[Read More]

Schulman IRB’s Central Oncology Review Division adds Judith Carrithers

Tuesday, October 4, 2016

Schulman IRB, a central IRB in customer service and technology, announced that Judith Carrithers, JD, MPA, will join its Central Oncology Review (COR) division October 15, 2016, as director of Oncology Services. Launching later in 2016, COR will provide collaborative, flexible IRB review services for oncology research centers seeking a more advanced level of partnership and service integration from a central IRB. [Read More]

2016 Lasker Awards honor scientists for basic and clinical medical research

Monday, September 26, 2016

The Albert and Mary Lasker Foundation has announced the winners of the 2016 Lasker Awards for medical science: William G. Kaelin, Peter J. Ratcliffe, and Gregg L. Semenza for basic medical research;Ralf F.W. Bartenschlager, Charles M. Rice, and Michael J. Sofia for clinical research; and Bruce M. Alberts for special achievement. The 2016 Lasker Awards, which carry an honorarium of $250,000 for each category, will be presented on Friday, September 23, in New York City.

[Read More]